M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells

Gain-of-function mutations in Kit receptor tyrosine kinase result in the development of a variety of cancers, such as mast cell tumours, gastrointestinal stromal tumours (GISTs), acute myeloid leukemia, and melanomas. The drug imatinib, a selective inhibitor of Kit, is used for treatment of mutant K...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Yasushi, Obata, Yuuki, Horikawa, Keita, Tasaki, Yasutaka, Suzuki, Kyohei, Murata, Takatsugu, Shiina, Isamu, Abe, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389679/
https://www.ncbi.nlm.nih.gov/pubmed/28403213
http://dx.doi.org/10.1371/journal.pone.0175514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389679/
https://www.ncbi.nlm.nih.gov/pubmed/28403213
http://dx.doi.org/10.1371/journal.pone.0175514

Ejemplares similares